Comparative Pharmacology
Head-to-head clinical analysis: D H E 45 versus NEXCEDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: D H E 45 versus NEXCEDE.
D.H.E. 45 vs NEXCEDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydroergotamine (DHE) is a semi-synthetic ergot alkaloid that acts as an agonist at serotonin (5-HT1B/1D) receptors, causing vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby aborting migraine attacks. It also has high affinity for alpha-adrenergic receptors and moderate affinity for dopamine D2 receptors.
NEXCEDE is a combination of omeprazole (proton pump inhibitor) and naproxen (nonsteroidal anti-inflammatory drug). Omeprazole irreversibly inhibits the gastric H+/K+-ATPase pump, reducing gastric acid secretion. Naproxen inhibits cyclooxygenase (COX)-1 and COX-2, decreasing prostaglandin synthesis, which reduces inflammation, pain, and fever.
1 mg intramuscularly or subcutaneously at first sign of headache, repeat hourly up to 3 mg per day, maximum 6 mg per week.
50-100 mg orally twice daily, with or without food. Maximum 200 mg/day.
None Documented
None Documented
2.5 hours (range 2-3.5 hours) for ergotamine; clinical context: short half-life supports its use in acute migraine, but frequent dosing risks ergotism.
Terminal elimination half-life is approximately 8 hours in patients with normal renal function. This supports twice-daily dosing. In patients with renal impairment (CrCl <30 mL/min), half-life may extend to 15-20 hours, requiring dose adjustment.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 90% of elimination, with 10% fecal.
Primarily renal excretion of unchanged drug (approximately 60% of the dose via glomerular filtration and tubular secretion). Biliary/fecal excretion accounts for about 30% of the dose. Less than 10% is metabolized.
Category C
Category C
Antimigraine Agent
Antimigraine Agent